IGF-1 LR3 (Long Arg3 Insulin-like Growth Factor-1) is a modified human IGF-1 analogue engineered with two structural changes: arginine substitution at position 3 (reducing affinity for IGF-binding proteins) and a 13-amino-acid N-terminal extension (further reducing IGFBP binding and improving plasma stability). The combined effect is a substantially extended biological half-life and an approximately three-fold increase in potency at the IGF-1 receptor compared with native IGF-1. The compound is widely used as a research tool in cell-culture systems for studying IGF-1 receptor pharmacology and in preclinical models of muscle, bone and metabolic biology.
IGF-1 LR3 binds and activates the IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase that triggers downstream PI3K/Akt/mTOR and Ras/MAPK signalling cascades — the central mitogenic and anabolic pathways of mammalian cells. The two structural modifications (Arg3 + N-terminal extension) reduce binding affinity for the IGF-binding proteins (IGFBP-1 through IGFBP-6) that normally sequester ~99% of circulating IGF-1, thereby substantially increasing the bioavailable fraction.
In cell-culture research, IGF-1 LR3 is the standard reagent for activating the IGF-1R because IGFBPs present in culture media bind native IGF-1 within minutes; the LR3 variant resists this sequestration and maintains receptor-activating activity across longer assay timeframes.
In muscle research specifically, IGF-1R activation triggers satellite-cell proliferation and protein-synthesis programmes — the basis for the muscle-hypertrophy research interest. The pathway also engages glucose-uptake mechanisms (insulin-receptor cross-talk) which explains the metabolic-research applications.
IGF-1 LR3 is the de-facto standard reagent for IGF-1R activation studies in cell culture. Native IGF-1 is rapidly sequestered by IGFBPs secreted into culture media within minutes of dosing; the LR3 variant maintains receptor-activating concentrations for the duration of typical assay protocols.
In bioprocessing research, IGF-1 LR3 is used as a growth factor in industrial cell-culture systems (notably CHO-cell biologics production), where its IGFBP resistance and extended half-life translate to more efficient receptor activation per unit dosed.
Preclinical muscle research has documented IGF-1 LR3-driven activation of satellite-cell proliferation, hypertrophy gene-expression programmes (e.g. MyoD, myogenin) and overall protein-synthesis flux in murine models. The IGF-1 axis is among the most studied muscle-hypertrophy pathways in published literature.
Beyond muscle, IGF-1 LR3 is used as a research probe for IGF-1's effects on bone formation (via osteoblast IGF-1R activation), glucose metabolism (insulin-receptor cross-talk), and neuronal survival (CNS IGF-1R signalling). Each represents a distinct active research line.